Industry sponsored symposium

Monday, 25 October

07:30 – 08:15 Davos 2

Industry sponsored symposium by Novartis

New Pharmacological Approaches for Lipid Lowering

Chairs: Francois Mach, Geneva / Christian Müller, Basel


Mendelian randomisation studies and optimal LDL target levels

Georg Ehret, Geneva

The ORION clinical programme

Ulf Landmesser, Berlin

How does RNA interfence and ASO work?

Thomas F. Lüscher, Zurich and London
12:00 – 13:15 Seehorn

Industry sponsored symposium by Bayer

Cyclic GMP in Heart Failure: A New Therapeutic Target?

Chairs: Mattia Arrigo, Zurich / Micha Maeder, St. Gallen

Introduction

Mattia Arrigo, Zurich

Cyclic GMP as regulator of the cardiovascular system

Harald H.H.W. Schmidt, Maastricht

Vericiguat in HFrEF: The VICTORIA Trial

Burkert Pieske, Berlin

How to use Vericiguat in clinical practice

Roger Hullin, Lausanne

Panel discussion

Key messages

Micha Maeder, St. Gallen
12:00 – 13:15 Schwarzhorn

Industry Sponsored Symposium by Amgen

How to reach new lipid targets in high risk patients?

Chairs: Christian Müller, Basel / Isabella Sudano, Zurich

The 2019 ESC Guidelines and the novel lipid targets

François Mach, Geneva

Indications, effectiveness and safety of PCSK9 inhibitors

Ulf Landmesser, Berlin

What is a normal cholesterol?

Thomas F. Lüscher, Zurich and London

To what degree are lipid targets reached in the real world

Thomas Rosemann, Zurich
18:00 – 19:15 Davos 2

Industry Sponsored Symposium by Sanofi

Lipid Management: State-of-the-Art

Chairs: François Mach, Geneva / Thomas F. Lüscher, Zurich and London

How to Implement the ESC Lipid Guidelines: Personalized Cholesterol Management

Konstaninos Koskinas, Bern / François Mach, Geneva

Impact of Lipid Lowering on Mortality

Christian Müller, Basel

New Avenues for Detection and Treatment of Vulnerable Plaques

Lorenz Räber, Bern